RepliCel Life Sciences, Inc. (RP) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

269.0 k

Shareholding (Jun 2018)

FII

0.02%

Held by 1 FIIs

DII

99.98%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals: Major

Market cap

CAD 1 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.14

Return on Equity

19.12%

Price to Book

-0.24

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2025)

Net Profit:

-8 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-89.66%

6 Months

-91.18%

1 Year

-91.73%

2 Years

-95.75%

3 Years

-95.79%

4 Years

-97.89%

5 Years

-99.34%

RepliCel Life Sciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

13.42%

EBIT to Interest (avg)

-3.00

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.14

Sales to Capital Employed (avg)

-0.10

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.02%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.24

EV to EBIT

-1.70

EV to EBITDA

-1.70

EV to Capital Employed

-0.44

EV to Sales

1.70

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

Bullish

No Signal

Bollinger Bands

Sideways

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2018

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.02%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -100.00% vs 0.00% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -1,466.67% vs 400.00% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.10",
          "val2": "-0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "0.80",
          "chgp": "-62.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.20",
          "val2": "0.60",
          "chgp": "-1,466.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-1,002.40%",
          "chgp": "100.24%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 66.67% vs 57.14% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.40",
          "val2": "0.40",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.40",
          "val2": "-1.40",
          "chgp": "71.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.90",
          "chgp": "-88.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.80",
          "val2": "2.30",
          "chgp": "-65.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.10",
          "val2": "-0.30",
          "chgp": "66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,018.00%",
          "val2": "-3,918.90%",
          "chgp": "290.09%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ

Mar'25

Dec'24

Change(%)

Net Sales

0.00

0.10

-100.00%

Operating Profit (PBDIT) excl Other Income

-0.10

Interest

0.00

Exceptional Items

0.30

0.80

-62.50%

Consolidate Net Profit

-8.20

0.60

-1,466.67%

Operating Profit Margin (Excl OI)

0.00%

-1,002.40%

100.24%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2025 is -100.00% vs 0.00% in Dec 2024

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is -1,466.67% vs 400.00% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.40

Operating Profit (PBDIT) excl Other Income

-0.40

-1.40

71.43%

Interest

0.10

0.90

-88.89%

Exceptional Items

0.80

2.30

-65.22%

Consolidate Net Profit

-0.10

-0.30

66.67%

Operating Profit Margin (Excl OI)

-1,018.00%

-3,918.90%

290.09%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 66.67% vs 57.14% in Dec 2023

All Annual Results

Company CV

About RepliCel Life Sciences, Inc.

RepliCel Life Sciences, Inc.

Pharmaceuticals: Major

Replicel Life Sciences Inc is a Canada-based regenerative medicine company. It develops autologous cell therapies that treat functional cellular deficits. Its product pipeline includes RCT-01-Tendon Repair, RCS-01-Skin Rejuvenation, RCH-01-Hair Regeneration and RCI-02-Dermal Injector. RCT-01 is an autologous cell-based treatment utilizing non-bulbar dermal sheath cells isolated from the hair follicle sheath to treat chronic tendinosis caused by acute and chronic tensile overuse. RCH-01 also utilizes dermal sheath cup cells isolated from the hair follicle to treat androgenetic alopecia. RCI-02 is a dermal injector designed to control intradermal (dermis), subcutaneous (fat) or intramuscular injections. It is designed to support the injection of RCH-01 and RCS-01 cell therapy products. The injector has applications for dermatological procedures requiring injections of specific volumes of material at specific depths, including cellular products, fillers and collagen injections.

Company Coordinates

Company Details

570 Granville St Suite 900 , VANCOUVER BC : V6C 3P1

Tel: 1 604 24886931 604 2488696

https://www.replicel.com/

Registrar Details